Boyd Peter E. 4

What Happened Peter E. Boyd, Chief People Officer of Aquestive Therapeutics, sold 29,814 shares in an open-market transaction on 2026-03-10 for a weighted average price of $4.17, totaling about $124,414. On 2026-03-09 he received two awards: 80,000 shares of restricted stock (reported at $0) and a derivative award covering 42,500 shares reported at $4.29 each (total reported value $182,325).

Key Details

• Dates and prices:
  • 2026-03-09: Award of 80,000 restricted shares @ $0 reported.
  • 2026-03-09: Derivative award of 42,500 shares @ $4.29 (reported value $182,325).
  • 2026-03-10: Sale of 29,814 shares @ weighted avg $4.17, proceeds ~$124,414 (sale executed in multiple trades at $4.17–$4.33). (F3)
• Shares owned after the transactions: not specified in the filing.
• Notable footnotes:
  • F1: The 80,000 restricted shares vest in three annual installments (25%/25%/50%).
  • F4: The derivative/options vesting schedule is also 25%/25%/50%.
  • F2: The 29,814-share sale was a mandatory "sell-to-cover" to satisfy tax withholding on vesting and was not a discretionary trade by the reporting person.
• Filing timeliness: Form filed 2026-03-11 for transactions on 2026-03-09/03-10 — not indicated as late.

Context These transactions reflect routine equity compensation activity: receipt of restricted stock and derivative awards (subject to multi-year vesting) and a mandated sell-to-cover to cover tax withholding. The sale appears to be procedural rather than a voluntary investment decision; awards vest over time and are not an immediate cash purchase/sale signal.